Cortical Lewy body disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 2, 2004, Pages 175-178

  Burn, D J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CARRIER PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CHROMOGRANIN; CHROMOGRANIN A; MONOCLONAL ANTIBODY; NERVE PROTEIN; SYNAPTOPHYSIN; SYNPHILIN 1; SYNPHILIN-1; SYNUCLEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN CORTEX; CELL POLARITY; CELLULAR DISTRIBUTION; CLINICAL FEATURE; COGNITIVE DEFECT; CORRELATION ANALYSIS; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; EDITORIAL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LEWY BODY; LIMBIC SYSTEM; METABOLISM; NERVE DEGENERATION; PARKINSON DISEASE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SENILE PLAQUE;

EID: 0842265975     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.025569     Document Type: Editorial

References (41)

1. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
2. Cummings JL. Intellectual impairment in Parkinson's disease: clinical, pathologic and biochemical correlates. J Geriatr Psychiatry Neurol 1988;1:24-36.
3. Aarsland D, Tandberg E, Larsen JP, et al. Frequency of dementia in Parkinson's disease. Arch Neurol 1996;53:538-42.
4. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease. Arch Neurol 2003;60:387-92.
5. Tsuang DW, Dalan AM, Eugenio CJ, et al. Familial dementia with Lewy bodies: a clinical and neuropathological study of two families. Arch Neurol 2002;59:1622-30.
6. Gwinn-Hardy K. Genetics of parkinsonism. Mov Disord 2002;17:645-56.
7. McKeith IG, Burn DJ. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. In: DeKosky ST, ed. Neurologic clinics: dementia, vol 18. Philadelphia: WB Saunders, 2000:865-83.
8. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
9. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 2001;102:355-63.
10. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-37.
11. Marui W, Iseki E, Nakai T, et al. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci 2002;195:153-9.
12. Katsuse O, Iseki E, Marui W, et al. Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J Neurol Sci 2003;211:29-35.
13. Katsuse O, Iseki E, Kosaka K. Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies. Neuropathology 2003;23:9-15.
14. McLean PJ, Kawamata H, Shariff S, et al. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem 2002;83:846-54.
15. Ishizawa T, Mattila P, Davies P, et al. Colocalisation of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003;62:389-97.
16. McNaught KS, Shashidharan P, Perl DP, et al. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2002;16:2136-48.
17. Schlossmacher MG, Frosch MP, Gai WP, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 2002;160:1655-67.
18. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
19. Gómez-Tortosa E, Newell K, Irizarry MC, et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999;53:1284-91.
20. Harding AJ, Halliday GM. Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathol Appl Neurobiol 1998;24:195-201.
21. Richard IH, Papka M, Rubio A, et al. Parkinson's disease and dementia with Lewy bodies: one disease or two? Mov Disord 2002;17:1161-5.
22. Colosimo C, Hughes AJ, Kilford L, et al. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:852-6.
23. Jellinger KA, Seppi K, Wenning GK, et al. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 2002;109:329-39.
24. SantaCruz K, Pahwa R, Lyons K, et al. Lewy body, neurofibrillary tangle and senile plaque pathology in Parkinson's disease patients with and without dementia [abstract]. Neurology 1999;52:A476-7.
25. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003;60:1586-90.
26. Mirra SS, Heyman A, McKeel DW, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardisation of the neuropathological assessment of Alzheimer's disease. Neurology 1991;41:479-86.
27. Working Group. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Aizheimer's Disease. Neurobiol Aging 1997;18:51-2.
28. Mastaglia FL, Johnsen RD, Byrnes ML, et al. Prevalence of amyloid-β deposition in the cerebral cortex in Parkinson's disease. Mov Disord 2003;18:81-6.
29. Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson's disease: a post-mortem study. Acta Neuropathol (Berl) 2003;105:415-19.
30. Mattila PM, Roytta M, Torikka H, et al. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol (Berl) 1998;95:576-82.
31. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391-403.
32. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-21.
33. Apaydin H, Ahlskog JE, Parisi JE, et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-12.
34. Weiner MF. Dementia associated with Lewy bodies: dilemmas and directions. Arch Neurol 1999;56:1441-42.
35. Masliah E, Rockenstein E, Veinbergs I, et al. β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001;98:12245-50.
36. Spillantini MG, Goedert M. Tau and Parkinson disease. JAMA 2001;286:2324-6.
37. Martin ER, Scott WK, Nance MA, et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 2001;286: 2245-50.
38. de Silva R, Hardy J, Crook J, et al. The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease. Neurosci Lett 2002;330:201-3.
39. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003;54:235-8.
40. Nitsch RM, Deng M, Tennis M, et al. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 2000,48:913-18.
41. Beach TG, Kuo YM, Schwab C, et al. Reduction of cortical amyloid beta levels in guinea pig brain after systemic administration of physostigmine. Neurosci Lett 2001;310:21-4.